Second Annual Food and Drug Administration Health Professional Organizations Conference, 47652-47653 [2012-19549]
Download as PDF
<![CDATA[
47652
Federal Register / Vol. 77, No. 154 / Thursday, August 9, 2012 / Notices
RECORD ACCESS PROCEDURES:
Direct inquiries as to whether this
system contains a record pertaining to
an individual to the Privacy Act Officer
either electronically, or by regular mail,
or facsimile. Submit electronic requests
at https://publicaccesslink.fhfa.gov/
palMain.aspx. The regular mail address
is: Privacy Act Officer, Federal Housing
Finance Agency, 400 7th Street SW.,
Washington, DC 20024. The facsimile
number is: 202–649–1073. For the
quickest possible handling, mark your
electronic submission, letter, or
facsimile and the subject line, envelope,
or facsimile cover sheet ‘‘Privacy Act
Request’’ in accordance with the
procedures set forth in 12 CFR part
1204.
CONTESTING RECORD PROCEDURES:
Direct inquiries as to whether this
system contains a record pertaining to
an individual to the Privacy Act Officer
either electronically, or by regular mail,
or facsimile. Submit electronic requests
at https://publicaccesslink.fhfa.gov/
palMain.aspx. The regular mail address
is: Privacy Act Officer, Federal Housing
Finance Agency, 400 7th Street SW.,
Washington, DC 20024. The facsimile
number is: 202–649–1073. For the
quickest possible handling, mark your
electronic submission, letter, or
facsimile and the subject line, envelope,
or facsimile cover sheet ‘‘Privacy Act
Request’’ in accordance with the
procedures set forth in 12 CFR part
1204.
RECORD SOURCE CATEGORIES:
Information is provided by
individuals accessing or using FHFA
telecommunication resources or
devices.
EXEMPTIONS CLAIMED FOR THE SYSTEM:
None.
Dated: August 1, 2012.
Edward J. DeMarco,
Acting Director, Federal Housing Finance
Agency.
[FR Doc. 2012–19572 Filed 8–8–12; 8:45 am]
BILLING CODE 8070–01–P
FEDERAL HOUSING FINANCE
AGENCY
tkelley on DSK3SPTVN1PROD with NOTICES
[No. 2012–N–11]
Use of Eminent Domain To Restructure
Performing Loans
AGENCY:
Federal Housing Finance
Agency.
Notice; input accepted.
ACTION:
The Federal Housing Finance Agency
(FHFA) oversees the Federal National
VerDate Mar<15>2010
16:38 Aug 08, 2012
Jkt 226001
Mortgage Association (Fannie Mae), the
Federal Home Loan Mortgage
Corporation (Freddie Mac), and the
Federal Home Loan Banks (Banks).
Fannie Mae and Freddie Mac (the
Enterprises) are operating in
conservatorships with a core mission of
supporting the housing market. FHFA’s
obligations, as conservator, are to
preserve and conserve assets of the
Enterprises and to minimize costs to
taxpayers. The Enterprises purchase a
large portion of the mortgages originated
in the United States and they hold
private label mortgage backed securities
containing pools of non-Enterprise
loans. The Banks likewise have
important holdings of such securities. In
addition, the Banks accept collateral
that consists of mortgages of member
financial firms pledged in exchange for
advances of funds.
FHFA Concerns
FHFA has significant concerns about
the use of eminent domain to revise
existing financial contracts and the
alteration of the value of Enterprise or
Bank securities holdings. In the case of
the Enterprises, resulting losses from
such a program would represent a cost
ultimately borne by taxpayers. At the
same time, FHFA has significant
concerns with programs that could
undermine and have a chilling effect on
the extension of credit to borrowers
seeking to become homeowners and on
investors that support the housing
market.
FHFA has determined that action may
be necessary on its part as conservator
for the Enterprises and as regulator for
the Banks to avoid a risk to safe and
sound operations and to avoid taxpayer
expense.
Among questions raised regarding the
proposed use of eminent domain are the
constitutionality of such use; the
application of federal and state
consumer protection laws; the effects on
holders of existing securities; the impact
on millions of negotiated and
performing mortgage contracts; the role
of courts in administering or overseeing
such a program, including available
judicial resources; fees and costs
attendant to such programs; and, in
particular, critical issues surrounding
the valuation by local governments of
complex contractual arrangements that
are traded in national and international
markets.
Input
FHFA will accept input from any
person with views on this subject
through its Office of General Counsel
(OGC), no later than September 7, 2012,
as the agency moves forward with its
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
deliberations on appropriate action.
Communications may be addressed to
FHFA OGC, 400 Seventh Street SW.,
Eighth Floor, Washington, DC 20024, or
emailed to FHFA OGC at
eminentdomainOGC@fhfa.gov.
Communications to FHFA may be made
public.
Dated: August 6, 2012.
Richard Hornsby,
Chief Operating Officer, Federal Housing
Finance Agency.
[FR Doc. 2012–19566 Filed 8–8–12; 8:45 am]
BILLING CODE 8070–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–N–0001]
Second Annual Food and Drug
Administration Health Professional
Organizations Conference
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of conference.
The Food and Drug Administration
(FDA) is announcing a conference for
representatives of health professional
organizations. Topics on the agenda
include an update on the FDA Safety
and Innovation Act (Pub. L. 112–144)
and an overview of FDA’s Network of
Experts (public/private partnerships).
The afternoon will consist of
interactive breakout sessions facilitated
by FDA staff from various Centers and
Offices, including a networking session
to meet FDA personnel.
DATES: Date and Time: The conference
will be held on October 4, 2012, from
9 a.m. to 4 p.m.
Location: The conference will be held
at FDA White Oak Campus, 10903 New
Hampshire Ave., Bldg. 31 Conference
Center, the Great Room (rm. 1503),
Silver Spring, MD 20993.
Contact Person: Janelle Derbis, Office
of Special Health Issues, Food and Drug
Administration, 10903 New Hampshire
Ave., Silver Spring, MD 20993, 301–
796–8460, email:
Janelle.Derbis@fda.hhs.gov.
Registration: Register at: https://
www.surveymonkey.com/s/
FDAConference. Please include the
name and title of the person attending,
the name of the organization, and email
address. There is no registration fee for
this conference. Early registration is
suggested because space is limited.
SUPPLEMENTARY INFORMATION: The aim of
the conference is to further the public
health mission of FDA through training,
E:\FR\FM\09AUN1.SGM
09AUN1
Federal Register / Vol. 77, No. 154 / Thursday, August 9, 2012 / Notices
collaboration, and structured discussion
between health professional
organizations and FDA staff. The Office
of Special Health Issues serves as a
liaison between FDA Centers and the
public on matters that involve medical
product safety and also acts as the
public’s link to information about the
medical product approval process.
The conference will include breakout
session topics from various FDA Centers
including a discussion on the usability
and content of FDA’s Web site,
information on what happens after you
submit a MedWatch report, protecting
patients from counterfeit and other
substandard drugs/supply chain threats,
and others. The goal of the breakout
sessions is to exchange ideas and to
encourage collaboration to promote
public health. Please indicate during
your registration the topics of greatest
interest to you for the breakout sessions.
If you need special accommodations
due to a disability, please inform Janelle
Derbis, Janelle.Derbis@fda.hhs.gov, at
least 7 days in advance of the
conference.
Dated: August 3, 2012.
Leslie Kux,
Assistant Commissioner for Policy.
Contact Person: Ai-Ping Zou, MD, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4118,
MSC 7814, Bethesda, MD 20892, 301–435–
1777, zouai@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Shared
Instrumentation: Ultrasound and Optical.
Date: September 7, 2012.
Time: 10 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Malgorzata Klosek, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4188,
MSC 7849, Bethesda, MD 20892, (301) 435–
2211, klosekm@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: August 2, 2012.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–19431 Filed 8–8–12; 8:45 am]
BILLING CODE 4140–01–P
[FR Doc. 2012–19549 Filed 8–8–12; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Institute of Arthritis and
Musculoskeletal and Skin Diseases;
Notice of Meeting
Center for Scientific Review; Notice of
Closed Meetings
tkelley on DSK3SPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Member
Conflict: Vascular Biology and Hematology.
Date: September 3, 2012.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
VerDate Mar<15>2010
16:38 Aug 08, 2012
Jkt 226001
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Arthritis and Musculoskeletal
and Skin Diseases Advisory Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
47653
Name of Committee: National Arthritis and
Musculoskeletal and Skin Diseases Advisory
Council.
Date: September 11, 2012.
Open: 8:30 a.m. to 12 p.m.
Agenda: To discuss administrative details
relating to the Council’s business and special
reports.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Conference
Room 6, Bethesda, MD 20892.
Closed: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Conference
Room 6, Bethesda, MD 20892.
Contact Person: Laura K. Moen, Ph.D.,
Director, Division of Extramural Research
Activities, NIAMS/NIH, 6700 Democracy
Boulevard, Suite 800, Bethesda, MD 20892,
301–451–6515, moenl@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.846, Arthritis,
Musculoskeletal and Skin Diseases Research,
National Institutes of Health, HHS)
Dated: August 1, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–19546 Filed 8–8–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
E:\FR\FM\09AUN1.SGM
09AUN1
]]>Agencies
[Federal Register Volume 77, Number 154 (Thursday, August 9, 2012)]
[Notices]
[Pages 47652-47653]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-19549]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2012-N-0001]
Second Annual Food and Drug Administration Health Professional
Organizations Conference
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of conference.
-----------------------------------------------------------------------
The Food and Drug Administration (FDA) is announcing a conference
for representatives of health professional organizations. Topics on the
agenda include an update on the FDA Safety and Innovation Act (Pub. L.
112-144) and an overview of FDA's Network of Experts (public/private
partnerships).
The afternoon will consist of interactive breakout sessions
facilitated by FDA staff from various Centers and Offices, including a
networking session to meet FDA personnel.
DATES: Date and Time: The conference will be held on October 4, 2012,
from 9 a.m. to 4 p.m.
Location: The conference will be held at FDA White Oak Campus,
10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room
(rm. 1503), Silver Spring, MD 20993.
Contact Person: Janelle Derbis, Office of Special Health Issues,
Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring,
MD 20993, 301-796-8460, email: Janelle.Derbis@fda.hhs.gov.
Registration: Register at: https://www.surveymonkey.com/s/FDAConference. Please include the name and title of the person
attending, the name of the organization, and email address. There is no
registration fee for this conference. Early registration is suggested
because space is limited.
SUPPLEMENTARY INFORMATION: The aim of the conference is to further the
public health mission of FDA through training,
[[Page 47653]]
collaboration, and structured discussion between health professional
organizations and FDA staff. The Office of Special Health Issues serves
as a liaison between FDA Centers and the public on matters that involve
medical product safety and also acts as the public's link to
information about the medical product approval process.
The conference will include breakout session topics from various
FDA Centers including a discussion on the usability and content of
FDA's Web site, information on what happens after you submit a MedWatch
report, protecting patients from counterfeit and other substandard
drugs/supply chain threats, and others. The goal of the breakout
sessions is to exchange ideas and to encourage collaboration to promote
public health. Please indicate during your registration the topics of
greatest interest to you for the breakout sessions.
If you need special accommodations due to a disability, please
inform Janelle Derbis, Janelle.Derbis@fda.hhs.gov, at least 7 days in
advance of the conference.
Dated: August 3, 2012.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2012-19549 Filed 8-8-12; 8:45 am]
BILLING CODE 4160-01-P
